Oncoinvent ASA (OSL:ONCIN)
Norway · Delayed Price · Currency is NOK 1.380
0.00 (0.00%)
At close: Jul 31, 2025
Oncoinvent ASA Company Description
Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer.
Its lead product candidate is Radspherin, alpha-radiation therapy candidate designed for the direct targeting of cancers that have spread to body cavities, like the peritoneum in two phase 1/2a trials and one randomized phase 2 trial.
The company was incorporated in 2010 and is based in Oslo, Norway.
Oncoinvent ASA
| Country | Norway |
| Founded | 2010 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 34 |
| CEO | Oystein Soug |
Contact Details
Address: Gullhaugveien 7 Oslo, 0484 Norway | |
| Phone | 47 22 18 33 05 |
| Website | oncoinvent.com |
Stock Details
| Ticker Symbol | ONCIN |
| Exchange | Oslo Børs |
| Fiscal Year | January - December |
| Reporting Currency | NOK |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Oystein Soug | Chief Executive Officer |
| Tore Kvam | Chief Financial Officer |
| Gro Hjellum | Chief Operating Officer |